Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable galactokinase GalK (galactose kinase) | 0.0051 | 1 | 1 |
Echinococcus granulosus | N acetylgalactosamine kinase | 0.0024 | 0.2298 | 0.2298 |
Schistosoma mansoni | galactokinase | 0.0024 | 0.2298 | 1 |
Mycobacterium ulcerans | galactokinase | 0.0051 | 1 | 1 |
Brugia malayi | galactokinase family protein | 0.0024 | 0.2298 | 1 |
Trypanosoma brucei | galactokinase-like protein, putative | 0.0034 | 0.5161 | 1 |
Trypanosoma cruzi | galactokinase, putative | 0.0051 | 1 | 1 |
Trichomonas vaginalis | galactokinase, putative | 0.0024 | 0.2298 | 0.5 |
Trichomonas vaginalis | galactokinase, putative | 0.0024 | 0.2298 | 0.5 |
Treponema pallidum | galactokinase | 0.0044 | 0.813 | 1 |
Loa Loa (eye worm) | galactokinase | 0.0024 | 0.2298 | 1 |
Leishmania major | galactokinase-like protein | 0.0051 | 1 | 1 |
Trichomonas vaginalis | galactokinase, putative | 0.0024 | 0.2298 | 0.5 |
Trichomonas vaginalis | galactokinase, putative | 0.0024 | 0.2298 | 0.5 |
Trypanosoma cruzi | galactokinase, putative | 0.0051 | 1 | 1 |
Echinococcus multilocularis | galactokinase | 0.0051 | 1 | 1 |
Trypanosoma cruzi | galactokinase-like protein, putative | 0.0044 | 0.813 | 0.813 |
Toxoplasma gondii | GHMP kinase, N-terminal domain-containing protein | 0.0024 | 0.2298 | 1 |
Trypanosoma cruzi | galactokinase, putative | 0.0044 | 0.813 | 0.813 |
Giardia lamblia | Mevalonate kinase | 0.0016 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase | 0.0016 | 0 | 0.5 |
Entamoeba histolytica | galactokinase, putative | 0.0051 | 1 | 0.5 |
Echinococcus multilocularis | N acetylgalactosamine kinase | 0.0024 | 0.2298 | 0.2298 |
Mycobacterium leprae | Probable 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase IspE (CMK) (4-(cytidine-5'-diphospho)-2-C-methyl-D-erythritol kinase) | 0.0016 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.